Xenical Evropska unija - madžarščina - EMA (European Medicines Agency)

xenical

cheplapharm arzneimittel gmbh - orlistat - elhízottság - antiobesity készítmények, diétás termékek - xenical együtt enyhén kalóriaszegény diéta elhízott betegek a testtömeg-index (bmi) nagyobb vagy egyenlő-hoz 30 kg/m2, vagy túlsúlyos betegek (bmi > 28 kg/m2) kapcsolódó kockázati tényezők kezelésére javallt. kezelés orlisztát meg kell szüntetni a 12 hét után, ha a beteg képtelen volt elveszíteni legalább 5% - a testsúly mérve a terápia megkezdése.

Zynquista Evropska unija - madžarščina - EMA (European Medicines Agency)

zynquista

guidehouse germany gmbh - sotagliflozin - cukorbetegség, 1-es típus - cukorbetegségben szedett gyógyszerek - zynquista jelzi kiegészítéseként az inzulin terápia javítja a glikémiás kontroll felnőttek az 1-es típusú diabetes mellitus a testtömeg-index (bmi) ≥ 27 kg/m2, aki nem sikerült elérni a megfelelő glikémiás kontroll annak ellenére, hogy optimális inzulin terápia.

Airexar Spiromax Evropska unija - madžarščina - EMA (European Medicines Agency)

airexar spiromax

teva b.v. - salmeterol, a flutikazon-propionát - pulmonary disease, chronic obstructive; asthma - gyógyszerek obstruktív légúti betegségek, - az airexar spiromax csak 18 éves és idősebb felnőttek számára javasolt. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. a krónikus obstruktív légúti betegség (copd)airexar spiromax javallt a tüneti kezelés a betegek copd-ben, a fev1.

Xenpozyme Evropska unija - madžarščina - EMA (European Medicines Agency)

xenpozyme

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - egyéb táplálkozási traktus pedig anyagcsere termékek, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.

Thyrogen Evropska unija - madžarščina - EMA (European Medicines Agency)

thyrogen

sanofi b.v. - az alfa-tirotropin - pajzsmirigy daganatok - a hypophysis elülső lebeny hormonjai, valamint analógok, agyalapi mirigy, vagy a hypothalamus hormonok, valamint analógok - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.

Dupixent Evropska unija - madžarščina - EMA (European Medicines Agency)

dupixent

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatitisellenes szerek, a kortikoszteroidok kivételével - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Nulibry Evropska unija - madžarščina - EMA (European Medicines Agency)

nulibry

tmc pharma (eu) limited - fosdenopterin hydrobromide dihydrate - metal metabolism, inborn errors - egyéb táplálkozási traktus pedig anyagcsere termékek, - nulibry is indicated for the treatment of patients with molybdenum cofactor deficiency (mocd) type a.

Levemir Evropska unija - madžarščina - EMA (European Medicines Agency)

levemir

novo nordisk a/s - detemir inzulin - diabetes mellitus - cukorbetegségben szedett gyógyszerek - cukorbetegség kezelése felnőtteknél, serdülőknél és 1 éves vagy annál idősebb gyermekeknél.